WaveMan
WaveMan · Company
LYRA · Lyra Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

LYRA Lyra Therapeutics (LYRA) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001327273
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Lyra Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Lyra Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Cavalier Jason
Chief Financial Officer
SELL
2026-01-08 SECtraded 2026-01-06
769
$2.6K
-95.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 10, 2025.
  • The trade is 0.1% of the 518,547 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: Chief Financial Officer Cavalier Jason sold about $2.6K of LYRA on Jan 6, 2026; 1 other insider sold within 30 days.
Palasis Maria
President & CEO
SELL
2026-01-08 SECtraded 2026-01-06
1,702
$5.7K
-95.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jul 10, 2025.
  • The trade is 0.2% of the 1,096,733 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: President & CEO Palasis Maria sold about $5.7K of LYRA on Jan 6, 2026; 1 other insider sold within 30 days.
PERCEPTIVE ADVISORS LLC
SELL
2025-11-13 SEC
28,597
$111.5K
-95.1%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on Nov 12, 2025.
  • The trade is 22.9% of the 124,859 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: Insider PERCEPTIVE ADVISORS LLC sold about $111.5K of LYRA on Nov 13, 2025; 1 other insider sold within 30 days.
PERCEPTIVE ADVISORS LLC
SELL
2025-11-13 SEC
3,213
$12.5K
-95.1%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on Nov 12, 2025.
  • The trade is 22.9% of the 14,026 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: Insider PERCEPTIVE ADVISORS LLC sold about $12.5K of LYRA on Nov 13, 2025; 1 other insider sold within 30 days.
PERCEPTIVE ADVISORS LLC
SELL
2025-11-13 SECtraded 2025-11-12
883
$3.6K
-95.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Nov 11, 2025.
  • The trade is 5.1% of the 17,239 shares held after it.
  • 1 other insider sold within 30 days.
Insider activity: Insider PERCEPTIVE ADVISORS LLC sold about $3.6K of LYRA on Nov 12, 2025; 1 other insider sold within 30 days.
36 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 31 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-74.1% year over year
below 96% of Medical Devices
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.1% of the float short (float per yahoo 2026-10-27) · 2.8 days to cover · settled 2026-10-15
below 80% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch LYRA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-97.0%12M
-100%-66%-32%+1%2025-102025-122026-022026-042026-062026-082026-10 2025-11-06 · EDELMAN JOSEPH sold $149.7K2025-11-13 · PERCEPTIVE ADVISORS LLC sold $111.5K2025-11-07 · EDELMAN JOSEPH sold $84.3K2025-11-10 · EDELMAN JOSEPH sold $75.5K2025-11-12 · PERCEPTIVE ADVISORS LLC sold $31.9K2025-11-11 · PERCEPTIVE ADVISORS LLC sold $20.6K2025-11-06 · EDELMAN JOSEPH sold $16.8K2025-11-13 · PERCEPTIVE ADVISORS LLC sold $12.5K2025-11-07 · EDELMAN JOSEPH sold $9.5K2025-11-10 · EDELMAN JOSEPH sold $8.5K2026-01-06 · Palasis Maria sold $5.7K2025-11-12 · PERCEPTIVE ADVISORS LLC sold $3.6K2026-01-06 · Cavalier Jason sold $2.6K2025-11-11 · PERCEPTIVE ADVISORS LLC sold $2.3K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LYRA: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in LYRA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LYRA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
4 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
0 active
2
Phase 3
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

LYRA financials

Revenue growth
-74.1%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$398.0K
four quarters, 2025-01-01 to 2025-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-6,595%
TTM net income over average of 2024-12-31 and 2025-12-31
Return on assets
-56.5%
TTM net income over average of 2024-12-31 and 2025-12-31
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-77.3%
operating income (EBIT proxy) over average of 2024-12-31 and 2025-12-31 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$398.0K$1.5M$1.6M$1.4M
Operating income-$31.0M-$96.3M-$67.1M-$56.3M
Net income-$28.9M-$93.4M-$62.7M-$55.3M
EPS (diluted)-18.62-71.75-1.26-1.83
Operating cash flow-$28.9M-$70.0M-$63.3M-$43.4M
Cash$15.9M$40.6M$22.4M$32.5M
SEC XBRL, fiscal years, as known on 2026-10-28

LYRA Stock Sonar score 3/7 axes

Find similar shapesCompare

LYRA ranks highest on risk and compliance (54th percentile) and profitability (17th), and lowest on growth (4th), among Medical Devices peers.

Profitability
17
Inputs
  • Return on equity-6595% · 1 pct, sector of 183
  • Return on assets-56.5% · 28 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-77.3% · 22 pct, sector of 188
Growth
4
Inputs
  • Revenue growth, YoY-74.1% · 4 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
54
Inputs
  • Short interest, % of float+1.1% · 76 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+14.2% · 32 pct, sector of 198
4 not measured: Financial health, Insider conviction, Institutional and government, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies